Dr. Alex Tatem
The Disruptor
Contrarian and drawn to the edge; challenges the settled answer.
Dr Alex Tatem reads as The Disruptor because he works at the contested frontier where urology meets emerging peptide medicine, championing treatments that mainstream practice has been slow to engage. He moves faster than institutional caution allows, using public platforms to challenge conservative prescribing norms and advance unconventional frameworks for male health optimisation.
“That's a great question. So officially, what happened is there was a meeting where they brought together the experts at the time and they said there is insufficient data for us to say that these are safe because again they had not gone through the full FDA approval process.”
“If we look at the top four large language models companies, all right, so all the heavy hitters and how much revenue they're generating, it's estimated to be between $58 billion up to maybe $62 billion. Yet the income and the revenue from just semaglutide and terzepatide alone is going to be over $55 billion this year.”
“Well, I mean, what is better, right? So I like this option for many of my patients because it's flexible, all right? So that is something that works for most patients, all right? But then again, this works great for patients too. But what you want is you want an ecosystem where you have choice.”
“United States from the FDA and trying to shut down compounding pharmacies and prevent them from making these medications even though that ability to customize the fact that this is not an exact copy of what's in your hand right now should protect it under current legislation, but there is now enough pressure from the powers that be and fr…”
The Diary of a CEO: “The Peptide Expert: Big Pharma Are Hiding This Powerful Peptide From You! - Dr. Alex Tatem”
LISTEN AT THE SOURCE ↗THE RECORD IS CHECKABLE